TOKYO, Jan. 24 /PRNewswire-FirstCall/ -- Medicsight Inc.'s majority owned subsidiary, Medicsight KK (“Medicsight”), announced today that it will initiate eight Japan clinical studies jointly sponsored by the Japan National Cancer Center under the leadership of Professor N. Moriyama, Director of the Cancer Screening Technology Division, National Cancer Center. These clinical studies represent a major step forward in the company’s plans to determine the performance of its unique ColonCAD and LungCAD software for Japanese patient groups.
“Medicsight is committed to ensuring our software is compatible with Japanese populations and is easy for Japanese radiologists to utilize. These studies with Japan National Cancer Center will help us demonstrate Medicsight’s commitment to the Japanese radiological community and further add to its reputation as a global leader in CAD and medical imaging analysis,” said David Sumner, Medicsight Asia CEO.
Sumner continued, “This series of trials will concentrate on showing how CAD can benefit radiologists in interpreting time consuming and difficult to read studies such as CT colonography and identifying lesions in the lung, such as nodules. It is the first time that such a series has taken place in Japan and we believe that it will further drive the adoption of CAD as being essential when reading these types of study.”
Medicsight’s CAD tools are designed to be seamlessly integrated into either 3D workstations or PACS and assist radiologists in the identification of potentially fatal lesions found in the lung and polyps found in the colon. By utilizing a ‘concurrent-read’ approach Medicsight CAD allows radiologists to review the original images simultaneously with regions of interest generated by CAD. There is already evidence that demonstrates that using a concurrent-read paradigm improves radiologist workflow and productivity.
-- Medicsight ColonCAD is an image-analysis software tool designed to be used with CT (computed tomography) colonography (virtual colonoscopy) to assist radiologists in detecting and measuring potential colorectal polyps. ColonCAD has been developed using one of the world’s largest CT scan databases and is the first concurrent-read CAD software available for CT Colonography. -- Medicsight LungCAD is a medical imaging software tool designed to assist radiologists in the evaluation of pulmonary nodules on CT scans of the lung. Developed using one of the world’s largest and most population-diverse CT scan databases, the product aims to assist radiologists in detecting lesions in the lung, such as nodule, while providing valuable information to the radiologist to assess patient images more effectively. LungCAD also utilizes a concurrent-read approach. -- The Medicsight ColonCAD and LungCAD applications are designed to be easily and seamlessly integrated into PACS or 3D workstation. Through this approach workflows are enhanced rather having to be completely relearned and image data does not have to be reloaded into a separate software applications to take advantage of the benefits of CAD. About Medicsight Medicsight Japan Office: Business Address: New Horizon Ebisu Bldg. 2nd Floor, 3-14-20 Higashi, Shibuya-ku, Tokyo 150-001 Date of Japan Establishment: March 25, 2005
Medicsight is a developer of enterprise computer-aided detection (CAD) software for the medical imaging market. Tested on one of the world’s largest databases of CT scan data, Medicsight’s software solutions help clinicians identify and measure suspicious lung lesions and colorectal polyps. The company’s CAD software products, LungCAD and ColonCAD, are designed to improve workflow and productivity using a concurrent-read feature that allows a clinician to review the original image simultaneously with the Medicsight CAD findings. Headquartered in London, Medicsight employs more than 60 people and also has offices in the United States, Japan, China, and Gibraltar. Product and company information can be found on http://www.medicsight.com . Stock symbol: MGT
Medicsight Inc.
CONTACT: David Sumner, Medicsight Asia CEO, +44-20-7598-4080, Investors,Stephanie Carrington, +1-646-536-7017, or Nick Laudico, +1-646-536-7030,Media (Japan), Sakura Tominaga or Masato Nagata, 03-3524-4600, or Media(U.S.A.), Lindsay Vidrine, +1-314-982-1723, all of Medicsight
Web site: http://www.medicsight.com/
